<DOC>
	<DOCNO>NCT01053169</DOCNO>
	<brief_summary>Beriplex® P/N make human plasma ( liquid part blood ) contain coagulation factor II , VII , IX X important blood clotting ( coagulation ) . Lack factor mean blood clot quickly increase tendency bleed . This observational study design evaluate effectiveness Beriplex® P/N prevention ( prophylaxis ) treatment bleed surgery ( perioperative bleeding ) routine clinical setting .</brief_summary>
	<brief_title>Observational Study Prophylaxis Treatment Acute Perioperative Bleeding With Beriplex® P/N ( Probe Study )</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Blood Loss , Surgical</mesh_term>
	<mesh_term>Coagulation Protein Disorders</mesh_term>
	<mesh_term>Thrombin</mesh_term>
	<criteria>Inclusion Criteria ( All ) : For cohort : •≥ 16 year age Received treatment : Beriplex® P/N FFP Beriplex® P/N ( subsequent order ) FFP INR and/or PT result available connection administration Beriplex® P/N FFP : within 3 hour directly administration Beriplex® P/N FFP In case Beriplex® P/N use subsequent FFP , additional result INR PT administration two product Cohort P ( Prophylaxis Group ) : Chronic liver disease , acute liver failure , condition require correction coagulopathy Coagulopathy ( INR &gt; 1.4 and/or PT ≥ 3 sec upper limit normal [ ULN ] ) Any plan major minimally invasive procedure , except liver transplantation Cohort T ( Treatment Group ) : Acute perioperative bleeding ( assessed investigator ) Treatment prothrombin complex concentrate ( PCCs ) Beriplex® P/N Acquired deficiency vitamin Kdependent coagulation factor ( e.g. , induced treatment oral vitamin K antagonist )</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Coagulopathy</keyword>
	<keyword>Perioperative bleeding</keyword>
	<keyword>Prothrombin complex</keyword>
	<keyword>Liver disease</keyword>
</DOC>